Zilucoplan: Dosing Protocols
Dosing guidelines, reconstitution, and administration information
๐TL;DR
- โข1 dosing protocols documented
- โขReconstitution instructions included
- โขStorage: Store refrigerated at 2-8 degrees C (36-46 degrees F) in original carton to protect from light. May be stored at room temperature up to 30 degrees C (86 degrees F) for a single period of up to 3 months. Do not freeze.
Protocol Quick-Reference
Generalized myasthenia gravis (anti-AChR antibody-positive adults)
Dosing
Amount
0.3 mg/kg body weight
Frequency
Once daily
Duration
Ongoing
Step-wise Titration
Administration
Route
SCSchedule
Once daily
Timing
Self-administer at approximately the same time each day. No dose titration required.
โ Rotate injection sites
Cycle
Duration
Ongoing
Repeatable
Yes
Preparation & Storage
โ Ready-to-use โ no reconstitution required
Storage: Refrigerate at 2-8 degrees C. May store at room temperature up to 30 degrees C for up to 3 months.
โ๏ธ Suggested Bloodwork (3 tests)
When:
Why:
When:
Why:
When:
Why:
๐ก Key Considerations
- โFDA-approved prescription medication available through ZILBRYSQ REMS
- โMeningococcal vaccination required at least 2 weeks before first dose
- โAvailable only through certified healthcare providers and pharmacies
- โWeight-based dosing with pre-filled syringes
Unlock dosing protocols
Free access to research-backed dosing information for all peptides.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
| Purpose | Dose | Frequency | Duration | Notes |
|---|---|---|---|---|
| Generalized Myasthenia Gravis (Anti-AChR Antibody-Positive Adults) | 0.3 mg/kg body weight subcutaneously once daily. Weight-based dosing with pre-filled syringes available in multiple strengths. | Once daily subcutaneous self-injection | Ongoing (chronic treatment for gMG management) | FDA-approved dose. Steady-state trough concentrations reached by 4 weeks. Achieves approximately 97.5% complement inhibition by end of first week. Meningococcal vaccination required at least 2 weeks before first dose. |
Unlock full dosage protocols
Free access to complete dosing tables and protocol details.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
๐Reconstitution Instructions
Zilucoplan (Zilbrysq) is supplied as a ready-to-use solution for subcutaneous injection in pre-filled syringes. No reconstitution is required. Available in multiple strengths to accommodate weight-based dosing.
Recommended Injection Sites
- โAbdomen
- โThigh
- โUpper arm (outer area)
๐งStorage Requirements
Store refrigerated at 2-8 degrees C (36-46 degrees F) in original carton to protect from light. May be stored at room temperature up to 30 degrees C (86 degrees F) for a single period of up to 3 months. Do not freeze.
Community Dosing Protocols
Compare these clinical doses with what 50+ community members report using.
Based on 50+ community reports
View community protocolsResearch Tools
Before You Begin
Review safety warnings and contraindications before starting any protocol.
Approved Dosing Information#
Zilucoplan (Zilbrysq) is an FDA-approved prescription medication for the treatment of generalized myasthenia gravis in anti-AChR antibody-positive adults. All dosing information reflects the approved prescribing information.
FDA-Approved Dose#
The approved dose of zilucoplan is 0.3 mg/kg body weight administered subcutaneously once daily. This dose was identified in the phase 2 dose-finding study and confirmed in the pivotal phase 3 RAISE trial.
Key Dosing Characteristics#
- Fixed weight-based dose: 0.3 mg/kg with no titration required
- Steady state: Trough plasma concentrations reached by approximately 4 weeks of daily dosing
- Complement inhibition: Approximately 97.5% complement inhibition achieved by end of the first week
- Time to peak concentration: 3-6 hours after subcutaneous injection
- Terminal half-life: Approximately 172 hours (~7 days)
Weight-Based Dosing Table#
| Body Weight Range | Daily Dose |
|---|---|
| 50 kg | 15 mg |
| 60 kg | 18 mg |
| 70 kg | 21 mg |
| 80 kg | 24 mg |
| 90 kg | 27 mg |
| 100 kg | 30 mg |
Pre-Treatment Requirements#
Before initiating zilucoplan, the following steps are required:
- Meningococcal vaccination: Complete vaccination for serogroups A, C, W, Y, and B at least 2 weeks before the first dose, unless the risks of delaying therapy outweigh the infection risk
- REMS enrollment: Prescriber, patient, and pharmacy must be enrolled in the ZILBRYSQ REMS program
- Patient education: Counsel patients on signs and symptoms of meningococcal infection and the need to seek immediate medical attention
Administration#
Self-Injection Technique#
- Remove the pre-filled syringe from the refrigerator and allow it to reach room temperature for approximately 30 minutes
- Select an injection site: abdomen, thigh, or outer upper arm
- Clean the injection site with an alcohol swab
- Pinch the skin and insert the needle at a 45-degree angle
- Inject the medication subcutaneously
- Rotate injection sites with each dose to minimize local reactions
Injection Timing#
- Administer at approximately the same time each day
- If a dose is missed, administer as soon as possible and then resume the regular daily schedule
- No specific requirement for administration with or without food
Monitoring Requirements#
| Parameter | Timing | Purpose |
|---|---|---|
| Meningococcal vaccination | Before treatment | Infection risk mitigation |
| Signs of meningococcal infection | Ongoing | Early detection of serious infection |
| MG symptom assessment | Regular visits | Efficacy monitoring |
| Injection site monitoring | Each injection | Local reaction assessment |
| CBC with differential | Periodic | Safety monitoring |
Treatment Considerations#
Concomitant Medications#
In the RAISE trial, zilucoplan was used concomitantly with standard gMG therapies including:
- Cholinesterase inhibitors (e.g., pyridostigmine)
- Corticosteroids
- Non-steroidal immunosuppressants (e.g., azathioprine, mycophenolate)
Treatment Interruption#
If zilucoplan treatment is interrupted, gMG symptoms may worsen. Patients should not discontinue treatment without consulting their healthcare provider. Upon reinitiation, complement inhibition is restored with resumption of daily dosing.
Special Populations#
- Renal impairment: No dose adjustment required based on available data
- Hepatic impairment: No dose adjustment required based on available data
- Elderly: No dose adjustment required; included in clinical trials
- Pediatric: Safety and efficacy not established in patients under 18 years
Related Reading#
Subscribe to see vendor options
Free access to verified vendor scores, pricing, and suppliers.
150+ peptide profiles ยท 30+ comparisons ยท 18 research tools
Protocol updates
Get notified when we update dosing protocols or publish related comparisons.
Frequently Asked Questions About Zilucoplan
Explore Further
Medical Disclaimer
This website is for educational and informational purposes only. The information provided is not intended to diagnose, treat, cure, or prevent any disease. Always consult with a qualified healthcare professional before using any peptide or supplement.